|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impaired debrisoquine metabolism resulting from defects in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene has been shown to be associated with the development of Parkinson's disease (PD).
|
9613747 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetically slow CYP2D6 metabolizers are at higher risk for developing Parkinson's disease, a risk that increases with exposure to pesticides.
|
20345925 |
2010 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast with the results from genotyping studies conducted among patients with an older age at onset, there were no significant differences in CYP2D6 allelic frequencies between young-onset PD cases and controls.
|
8710083 |
1996 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
|
28871472 |
2017 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
|
8291573 |
1993 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using allele-specific multiplex PCR, we genotyped 186 subjects for CYP2D6 *3, *4, *6, *7, and *8 alleles in order to estimate allelic, genotype and predicted phenotype frequencies in the control and patient groups, and to investigate the possible statistical difference between Parkinson's disease patients (n=41) and healthy controls (n=145).
|
11097352 |
2000 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results argue against a significant role of the CYP2D6 gene in the aetiology of sporadic and familial idiopathic parkinsonism in this patient population.
|
8937349 |
1996 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Polymorphic activities of debrisoquine 4-hydroxylase were suggested to be associated with some complex diseases, such as cancer and Parkinson's disease.
|
11702057 |
2001 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.
|
23258538 |
2013 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, a borderline significant influence of the CYP2D6 polymorphisms on PD risk was observed (OR: 1.07, 95%CI: 0.99-1.16, p=0.106).
|
24211060 |
2014 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The combined alleles frequency of CYP2D6*3 + apoE4 was significantly higher not only in the PD group (33.3%) but also in patients with parkinsonism (22.3%) compared to control subjects (1.6%).
|
10353349 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.
|
17270484 |
2007 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease.
|
15061826 |
2004 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
By contrast with the common occurrence of polymorphism of the CYP2D6 gene (a gene involved with xenobiotic metabolism) in white people, it is very rare in China and is not thought to be a significant factor contributing to Parkinson's disease in Chinese people.
|
9810958 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, epidemiological studies from China have shown that the prevalence of PD is much lower than in the Caucasian population, explained by the low frequency of cytochrome P-450 CYP2D6 debrisoquine hydroxylase gene polymorphism.
|
15829184 |
2005 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No significant association was found between CYP2D6 genotype and PD, but subjects with extensive metabolizer (EM) CYP2D6 phenotype, and the variant GSTP1*B genotype were at significantly higher PD risk than the corresponding poor or intermediary metabolizers (CYP2D6 poor metabolizer phenotype+intermediary metabolizers).
|
17250723 |
2007 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we show that the mitochondrially targeted CYP2D6 can efficiently catalyze MPTP-mimicking compounds, <i>i.e.</i> 2-methyl-1,2,3,4-tetrahydroisoquinoline, 2-methyl-1,2,3,4-tetrahydro-β-carboline, and 9-methyl-norharmon, suspected to induce PD in humans.
|
31113867 |
2019 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The CYP2D6 B mutation may be involved in pathogenesis of LBV and PD in a dominant-negative manner, or in the linkage disequilibrium of the CYP2D microsatellite to another pathogenic gene locus.
|
9633694 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Whilst an elevated frequency of the CYP2D6*4 allele was found in Parkinson's disease, no such elevations were found in DLB or Alzheimer's disease.
|
10208640 |
1999 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the CYP2D6 locus is not the major determinant of genetic susceptibility in familial Parkinson's disease.
|
8057112 |
1994 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Further, cases carrying combination of heterozygous genotypes of CYP2D6*4 or CYP2D6*10A(188C > T) and NAT2*5 were found to be at significantly higher risk for PD demonstrating the importance of gene-gene interactions in determining susceptibility to PD.
|
20364044 |
2010 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, reports of associations between alleles of the CYP2D6 locus (nearby on 22q13) and IPD, although inconsistent, indicated that an IPD susceptibility locus might be in strong linkage disequilibrium with CYP2D6.
|
9630632 |
1998 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of Parkinson's disease (PD) with two genes encoding liver-detoxifying enzymes, debrisoquine 4-hydroxylase (CYP2D6) and N-acetyltransferase 2 (NAT2), and with one gene related to Alzheimer's disease, apolipoprotein E (APOE).
|
10928584 |
2000 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Despite several recent meta-analyses showing an association between several polymorphisms in genes related with detoxification mechanisms such as cytochrome P4502D6 (CYP2D6), and glutathione transferases M1 and T1 (GSTM1, and GSTT1), data on NAT2 gene polymorphisms obtained from the current meta-analysis do not support a major association with PD risk, except in Asian populations.
|
27216438 |
2016 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate that CYP2D6, CYP1A2 and, to a lesser extent CYP3A4, may have a role in protecting against Parkinson's disease induced by MPTP and other potential environmental neurotoxins.
|
8627546 |
1996 |